China NMPA Drug Inspection - Heilongjiang Shenge Pharmaceutical Co., Ltd. - Yinqiao Cold Capsules

The Beijing Municipal Drug Administration published an announcement on January 16, 2020, detailing the results of its drug quality and safety supervision and sampling inspections conducted during the second half of 2019. These inspections were carried out in accordance with the "Implementation Plan for the 2019 Beijing 'Two Products and One Medical Device' Sampling Inspection Work," targeting drug manufacturers, wholesalers, and retail chains across the city. Over the full year 2019, a total of 2000 drug batches were sampled and tested. The announcement highlighted that 55 batches of drugs selected for the national centralized procurement pilot program underwent full coverage sampling and all were found compliant.

However, out of 403 batches sampled for regulatory purposes in the second half of 2019, two were identified as non-compliant. Specifically, a batch (190126) of Erythromycin Ointment, manufactured by Ma Yinglong Pharmaceutical Group Co., Ltd. and sampled from Beijing Xuannei Pharmaceutical Co., Ltd., failed the content determination test based on the Chinese Pharmacopoeia 2015 Edition. Additionally, Yinqiao Cold Capsules, batch 20181002, produced by Heilongjiang Sunflower Pharmaceutical Co., Ltd. and sampled from Beijing Jingmeng Huikang Pharmaceutical Co., Ltd., were found non-compliant regarding the total number of molds and yeasts, also against the Chinese Pharmacopoeia 2015 Edition. The identification of these quality deficiencies necessitates corrective actions from the implicated manufacturers to ensure product quality and regulatory adherence.